Abstract
US pharmaceutical HUB-services have emerged as key to assisting practitioners and patients overcome a multitude of obstacles; thus, achieving better patient compliance and experience. HUBs prove especially vital for patients on specialty therapies. However, in many Ex-US countries, market nuances do not lend themselves to the concept of HUBs, and companies are uncertain about their benefit. The aim of this study is to determine what aspects of US patient service HUBs can be adapted to increase patient access, education, and compliance in other geographies.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call